TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04605289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lemongrass essential oil gel
Description: The lemongrass oil gel will be administered by means of a syringe with a bent, blunt-end needle. The needle will be carefully inserted into the periodontal pocket and the gel will be applied in the test sites in a gentle probing manner, attempting to fill the full extent of the pocket. The gel will be applied up to the gingival margin and the excess gel will be removed with sterile gauze.~Periodontal dressing will be applied after the delivery of the drug, and they will be also asked not to eat for thirty minutes.~After placement of the gel in situ, patients will be instructed to follow strict oral hygiene protocol and not chew hard or sticky foods at the gel placement sites for rest of the week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be administered by means of a syringe with a bent, blunt-end needle. The needle will be carefully inserted into the periodontal pocket and the gel will be applied in the test sites in a gentle probing manner, attempting to fill the full extent of the pocket. The gel will be applied up to the gingival margin and the excess gel will be removed with sterile gauze.~Periodontal dressing will be applied after the delivery of the drug, and they will be also asked not to eat for thirty minutes.~After placement of the gel in situ, patients will be instructed to follow strict oral hygiene protocol and not chew hard or sticky foods at the gel placement sites for rest of the week.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: Conventional mechanical treatment by ultra-sonic scalers

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Scaling and root planing
Description: Conventional mechanical treatment by ultra-sonic scalers
Study: NCT04996446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: In experimental group, patients who meet the inclusion criteria will receive ALPPS stage I surgery, treated with Tislelizumab 2-4 weeks after stage I surgery, and receive ALPPS stage II surgery 2-4 weeks after Tislelizumab treatment, and treated with Tislelizumab q3W 6-12 months after stage II surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ALPPS surgery
Description: In experimental group, patients who meet the inclusion criteria will receive ALPPS stage I surgery, and receive ALPPS stage II surgery 4-8 weeks after stage I surgery; In control group, patients who meet the inclusion criteria will receive ALPPS stage I surgery, and receive ALPPS stage II surgery 3-6 weeks after stage I surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ALPPS surgery
Description: In experimental group, patients who meet the inclusion criteria will receive ALPPS stage I surgery, and receive ALPPS stage II surgery 4-8 weeks after stage I surgery; In control group, patients who meet the inclusion criteria will receive ALPPS stage I surgery, and receive ALPPS stage II surgery 3-6 weeks after stage I surgery.
Study: NCT01853202

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise training
Study: NCT00133809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transplantation of Human Islets
Description: Human islets, at least 9,000 islet equivalents per kilogram of body weight. Transplant involves surgical procedure
Study: NCT03005353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cumin seed extract
Description: patients will receive the drug in suppository form

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clotrimazole
Description: patients will receive the drug in suppository form
Study: NCT03589807

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H7N9
Description: Monovalent split 2017 A/H7N9 Inictivated Influenza Virus vaccine containing the HA and NA from low pathogenic avian influenza A/Hong Kong/125/2017 (H7N9) and the PB2, PB1, PA, NP, M and NS from A/Puerto Rico/8/1934 (H1N1).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H7N9
Description: Monovalent split 2017 A/H7N9 Inictivated Influenza Virus vaccine containing the HA and NA from low pathogenic avian influenza A/Hong Kong/125/2017 (H7N9) and the PB2, PB1, PA, NP, M and NS from A/Puerto Rico/8/1934 (H1N1).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H7N9
Description: Monovalent split 2017 A/H7N9 Inictivated Influenza Virus vaccine containing the HA and NA from low pathogenic avian influenza A/Hong Kong/125/2017 (H7N9) and the PB2, PB1, PA, NP, M and NS from A/Puerto Rico/8/1934 (H1N1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS03
Description: AS03 oil-in-water emulsion adjuvant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS03
Description: AS03 oil-in-water emulsion adjuvant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS03
Description: AS03 oil-in-water emulsion adjuvant.
Study: NCT02517814

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Study: NCT01340248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dilatrend 64mg capsule
Description: 1. Dilatrend 64mg capsule during fasting + Dilatrend 64mg capsule after high fat diet~2. Dilatrend 64mg capsule after high fat diet + Dilatrend 64mg capsule during fasting
Study: NCT04376151

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acceptance and Commiment Therapy (ACT) bibliotherapy 'Get Out of Your Mind and Into Your Life'
Description: The intervention has been described in the arm/group descriptions.
Study: NCT01920477

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Ofatumumab (human monoclonal antibody) was provided in prefilled glass syringes initial syringes contained 0.6ml (60mg) of concentration 100 mg/m: drug product subsequently modified to 0.4 mL (20mg) concentration (50mg/ML) drug product

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match the active doses will consist of prefilled glass syringes filled with normal saline.
Study: NCT01002677

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advocacy training curriculum
Description: Day-long presentation of an advocacy training curriculum by the state's Brain Injury Association staff: One session per month for 4 consecutive months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-directed
Description: Day-long group-based self-directed advocacy training activity: One session per month for 4 consecutive months.
Study: NCT00132899

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate and infliximab combination

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo and infliximab combination therapy.
Study: NCT02801695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citrulline
Description: Citrulline supplementation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01828905

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CERAMENT™|BONE VOID FILLER
Description: ceramic bone void filler

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous cancellous bone graft
Description: autologous cancellous bone graft
Study: NCT03956251

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined Mineralized/Demineralized Putty Allograft
Description: At time of extraction, 15 test patients will receive ridge preservation using Combined Mineralized/Demineralized Putty Allograft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Demineralized Putty Allograft
Description: At time of extraction, 15 control patients will receive ridge preservation using Demineralized Putty Allograft
Study: NCT00453167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80mg/m2 iv on day 1 and 8, every 3 weeks until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m2 iv on day 1 and 8, every 3 weeks until disease progression
Study: NCT04056988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren Lipid Microsphere
Description: Perflutren lipid microsphere preparation is an ultrasound contrast agent. Ultrasound contrast agents are used to help provide a clear picture during ultrasound.
Study: NCT00211068

Intervention type: DRUG
Intervention: No intervention
Description: This study is an observational study. No medication will be provided or administered to the participants. Participants will receive standard-of-care treatment from their individual physicians.
Study: NCT02537210

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalazine
Description: Patients will be prescribed Asacol 2g daily for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Patients will be prescribed placebo 5 capsules daily for 12 months
Study: NCT00004853

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: 5 microgram/kg/dose SC daily starting 24-36 hours after last dose of chemotherapy until post-nadir ANC \>=10,000/microliter

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim-SD/01
Description: 100 microgram/kg SC 24-36 hours after last dose of chemotherapy (single dose)
Study: NCT01718808

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab 500 mg/m2 every second week (days 1, 15, 29, etc.) until progression or unacceptable toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab 500 mg/m2 every second week (days 1, 15, 29, etc.) until progression or unacceptable toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m2 bid p.o. (750 mg/m2 if creatinine clearance 30-50 ml/min according to Cockroft-Gault formula, on days 1-14 every 3 weeks, restart on day 22
Study: NCT01666587

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Antioxidant

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Antioxidant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prostaglandin inhibitor (Ibuprophen)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prostaglandin inhibitor (Ibuprophen)
Study: NCT03621462

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence Dermatology Assistant (AIDA™)
Description: The Artificial Intelligence Dermatology Assistant (AIDA™) collects conventional demoscopic images and images at various spectral bands. Following image acquisition, the AIDA™ software presents users with (1) similar lesion images from the International Skin Imaging Collaboration archive, (2) Hypodermoscopy™ images, and (3) images providing an indication of lesion depth, based on the spectral data.
Study: NCT04245553

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Abdominal Point of Care Ultrasound
Description: Participants will be have their needle insertion site for a paracentesis land-marked using both the traditional anatomical method, and with a point of care ultrasound. Note that the current standard of care does not require the use of point of care ultrasound.
Study: NCT00918879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Oral tablet, once daily for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet, once daily for 24 weeks
Study: NCT01431820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luliconazole Solution, 10%
Description: Topical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luliconazole Solution, 10%
Description: Topical

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Solution
Description: Topical

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Solution
Description: Topical
Study: NCT03981848

Intervention type: OTHER
Intervention: Risk model of tumor relapse
Description: High risk factor model of tumor relapse after liver transplantation

Intervention type: OTHER
Intervention: Risk model of tumor relapse
Description: High risk factor model of tumor relapse after liver transplantation
Study: NCT00402012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: During the double-blind, 12 weeks treatment period, subjects will self-administer study medication (pioglitazone or equivalent volume of placebo) 30 mg/day each morning. The dose of pioglitazone will be increased to 45 mg/day after 4 weeks if the fasting plasma glucose is higher than 100mg/dl or the HbA1C is higher than 7%. This dose has proven tolerability, safety and efficacy for type 2 diabetes and has previously been used at the Pennington Center in studies on pioglitazone.
Study: NCT03211234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.0 mg DE-122 Injectable Solution + Lucentis
Description: Subjects will receive 6 monthly intravitreal injections of low dose DE-122 in the study eye, in combination with Lucentis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4.0 mg DE-122 Injectable Solution + Lucentis
Description: Subjects will receive 6 monthly intravitreal injections of high dose DE-122 in the study eye, in combination with Lucentis.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Lucentis
Description: Subjects will receive 6 monthly intravitreal injections of Sham in the study eye, in combination with Lucentis.
Study: NCT03814577

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Total Antioxidant Status
Description: Total Antioxidant Status values will be determined using a novel automated measurement method. The colour intensity, which can be measured spectrophotometrically, is related to the total amount of oxidant molecules present in the sample. The assay is calibrated with hydrogen peroxide) and the results are expressed in terms of micromolar hydrogen peroxide equivalent per litre.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Total Antioxidant Status
Description: Total Antioxidant Status values will be determined using a novel automated measurement method. The colour intensity, which can be measured spectrophotometrically, is related to the total amount of oxidant molecules present in the sample. The assay is calibrated with hydrogen peroxide) and the results are expressed in terms of micromolar hydrogen peroxide equivalent per litre.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Total Oxidant Status
Description: Total Oxidant Status values will be determined using a novel automated measurement method. The colour intensity, which can be measured spectrophotometrically, is related to the total amount of oxidant molecules present in the sample. The assay is calibrated with hydrogen peroxide) and the results are expressed in terms of micromolar hydrogen peroxide equivalent per litre.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Total Oxidant Status
Description: Total Oxidant Status values will be determined using a novel automated measurement method. The colour intensity, which can be measured spectrophotometrically, is related to the total amount of oxidant molecules present in the sample. The assay is calibrated with hydrogen peroxide) and the results are expressed in terms of micromolar hydrogen peroxide equivalent per litre.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bispectral Index
Description: Bispectral Index is a method for depth of anesthesia and assessment of sedation. The values of bispectral index decreases with the deepening of anesthesia. The values of 40-60 characterize the appropriate depth of anesthesia.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bispectral Index
Description: Bispectral Index is a method for depth of anesthesia and assessment of sedation. The values of bispectral index decreases with the deepening of anesthesia. The values of 40-60 characterize the appropriate depth of anesthesia.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Invasive arterial monitorization
Description: Invasive arterial monitorization will be performed to right radial artery under local anesthesia to follow up hemodynamic changes and take the blood samples.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Invasive arterial monitorization
Description: Invasive arterial monitorization will be performed to right radial artery under local anesthesia to follow up hemodynamic changes and take the blood samples.
Study: NCT02277054

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Collagen-MPC cornea
Description: Patients will undergo surgery using conventional anterior lamellar keratoplasty technique: diseased cornea will be trephined to approximately 50-90% of corneal thickness (depending on corneal ulcer or scar depth) and then a lamellar dissection will be created. Trephine diameter will depend on ulcer or leukoma maximal size. Alternatively a femtosecond laser may be used to create the dissection. A collagen-phosphorylcholine cornea 250-500 microns thick and equal or 0.25 mm larger diameter is placed and sutured. The sutures are superimposed and the implant and the sutures covered with a bandage contact lens. The sutures and bandage lens will be removed later after the initial healing period of 4 weeks or as determined by physician depending on the implant epithelial coverage.
Study: NCT00699153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loteprednol Etabonate
Description: Loteprednol Etabonate in an ophthalmic base will be administered to study eye 4 times a day(QID) for 14 days.
Study: NCT03589807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS03
Description: AS03 oil-in-water emulsion adjuvant.
Study: NCT00699153

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of Ophthalmic Loteprednol Etabonate
Description: Vehicle of ophthalmic loteprednol etabonate administered postoperatively to study eye 4 times a day(QID) for 14 days.
Study: NCT02468362

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic intersphincteric resection
Description: laparoscopic intersphincteric resection for low rectal cancer

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open intersphincteric resection
Study: NCT03004001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: 150 mg biweekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alirocumab placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 20 mg/day
Study: NCT03589807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS03
Description: AS03 oil-in-water emulsion adjuvant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS03
Description: AS03 oil-in-water emulsion adjuvant.
Study: NCT03004001

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: 20 mg/day
Study: NCT00527358

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SAFER (Seguridad, Apoyo, Familia, Educacion, y Recursos)
Description: 1. community lay workers will do family outreach and assist families in networking with other families and accessing community services, facilitating parent-youth and family-school communication and homework help for children, and help with translation of school or government/official notices;~2. youth leaders will provide a supportive presence, help youth navigate the system at school so that they can get help if needed, disseminate information about job training and possibilities, provide education about avoiding violence;~3. school support services will offer academic support, acculturation orientation, language, conflict resolution skills training, advocacy and referrals;~4. Youth drop-in center will provide youth with an adult supervised place to hang out, do homework, or participate in sports and job training.
Study: NCT03589807

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013
Description: Monovalent split 2013 A/H7N9 Inavtivated Influenza Virus vaccine containing the HA and NA from avian influenza A/Shanghai/2/2013 (H7N9) and the PB2, PB1, PA, NP, M and NS from A/Puerto Rico/8/1934 (H1N1).
Study: NCT02936726

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise, Health Coaching and Meditation
Description: Comparing Exercise, Health Coaching and Meditation In Combination

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise and Health Coaching
Description: Comparing Exercise and Health Coaching Alone
Study: NCT03589807

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013
Description: Monovalent split 2013 A/H7N9 Inavtivated Influenza Virus vaccine containing the HA and NA from avian influenza A/Shanghai/2/2013 (H7N9) and the PB2, PB1, PA, NP, M and NS from A/Puerto Rico/8/1934 (H1N1).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013
Description: Monovalent split 2013 A/H7N9 Inavtivated Influenza Virus vaccine containing the HA and NA from avian influenza A/Shanghai/2/2013 (H7N9) and the PB2, PB1, PA, NP, M and NS from A/Puerto Rico/8/1934 (H1N1).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phosphate Buffered Saline (PBS) diluent
Description: Diluent for Influenza Virus Vaccine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phosphate Buffered Saline (PBS) diluent
Description: Diluent for Influenza Virus Vaccine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phosphate Buffered Saline (PBS) diluent
Description: Diluent for Influenza Virus Vaccine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phosphate Buffered Saline (PBS) diluent
Description: Diluent for Influenza Virus Vaccine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phosphate Buffered Saline (PBS) diluent
Description: Diluent for Influenza Virus Vaccine.
Study: NCT03517943

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-SAG)
Description: Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-SAG)
Description: Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-Heist)
Description: Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-Heist)
Description: Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)
Study: NCT03592043

Intervention type: DEVICE
Intervention: MitraClip
Description: Transcatheter Mitral Valve Repair with MitraClip